Xoma, Takeda extend antibody pact

Xoma and Japan-based Takeda Pharmaceutical are expanding the antibody-discovery collaboration agreement the companies originally inked in November. At that time, Takeda's pact with Xoma was worth up to $100 million before royalties. Xoma estimates the aggregate upfront, R&D funding, milestone and other payments could exceed $230 million before royalties over the life of the agreement. "Xoma is well positioned to capitalize on the growing demand for monoclonal antibody solutions and this expanded agreement validates our strengths in translating targets into therapeutic product candidates and advancing their development thereafter," said John L. Castello, chairman of the board, president and CEO of Xoma.

- see the companies release for more

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.